Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data

Document Type : Short Communications


1 Department of Haematology, Great Western Hospitals NHS Trust, Swindon, UK.

2 Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

3 Department of Haematology, University Hospitals of Bristol NHS Trust, UK.

4 Department of Internal Medicine, Liaquat College of Medicine & Dentistry, Karachi, Pakistan.

5 Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.


We present the first-ever autologous stem cell transplantation (ASCT) outcome data from a secondary-care
healthcare facility. Albeit exact details of patient and disease characteristics and co-morbidity scores for all patients
are not available, the engraftment and survival data is very similar to those published from large tertiary-care cancer
centres, both regionally and internationally. Transplant Related Mortality (TRM) of 3.1% is within the expected range
and includes a patient who died of acute drug reaction (ADR) during conditioning chemotherapy, prior to the ASCT.
Furthermore, cyclophosphamide mobilization chemotherapy is given in the outpatient setting. This study is important in
terms of healthcare resource optimization as well as patients’ convenience and highlights that ASCT can be performed
in a safe and effective manner with comparable survival rates even at a DGH, provided the centre stays abreast with
the recent developments and can offer its patients with standard of care treatment of the era.


Main Subjects